Companies
KALA BIO signs U.S. ophthalmology testing distribution deal with Virotek
The five-year commercial agreement gives Kala exclusive U.S. distribution rights, subject to a September 2027 milestone, and half of net profit after Virotek recovers its cost of goods sold.